Back to All

Webinar: The Road to Recovery - How COVID-19 has impacted the global oncology diagnostic testing environment

11 September, 2020

As China emerges out of COVID-19, Diaceutics has investigated the impact of the pandemic on cancer testing and what the data reveals about challenges ahead for pharma and labs. Using this framework, we extended the analysis of cancer testing rates to the US to evaluate the short and long term impacts of the cancer test and treatment landscape with support from our partners Kantar Health. Insights and recommendations are sourced from the world’s largest repository of diagnostic testing data by Diaceutics.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny